Source comparison
Does PT-141 Help Low Libido: Quick Comparison
Primary Mechanism Activates MC4R in hypothalamus, increases dopamine signaling Inhibits PDE5, increases blood flow to genital tissue Replaces deficient endogenous testosterone PT-141 acts centrally on desire; PDE5 acts peripherally on function; TRT corrects ho
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Activates MC4R in hypothalamus, increases dopamine signaling
- Inhibits PDE5, increases blood flow to genital tissue
- Replaces deficient endogenous testosterone
- PT-141 acts centrally on desire; PDE5 acts peripherally on function; TRT corrects hormone deficiency
- Indication
- Low sexual desire (hypoactive sexual desire disorder)
- Erectile dysfunction, inadequate arousal
- Clinically low testosterone (<300 ng/dL)
- PT-141 treats motivation; others treat capability or hormonal substrate
- Onset of Action
- 45–90 minutes post-injection
- 30–60 minutes oral
- 2–4 weeks for subjective effects
- PT-141 and PDE5 are on-demand; TRT requires sustained therapy
- Efficacy in Women
- 60% response rate (RECONNECT trial)
- Minimal to no effect (not FDA-approved for women)
- Variable. Depends on baseline androgen levels
- PT-141 is the only FDA-approved medication for female low libido
- Side Effects
- Nausea (40%), flushing, headache
- Headache, flushing, visual disturbances
- Acne, mood changes, cardiovascular risks with prolonged use
- PT-141 side effects are acute and resolve; TRT risks are long-term